Friday, September 29, 2023


Biotechnology News Magazine

Allied BioScience Continues Focus on Saving Lives – Expands Globally

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

March 30, 2021

Allied BioScience is growing significantly as the innovative biotech firm commits to expanding regulatory approvals for the use of SurfaceWise2™ nationally and abroad to meet demand while diversifying the lineup of products beyond antimicrobial surface coatings.

As global demand for SurfaceWise2 continues to expand, the company has strategic partnerships in Canada, Germany, Australia, India and the United Arab Emirates, with more in the pipeline. Spanning industries including transportation, healthcare, fitness and retail, leading partners in these countries plan to distribute and apply the surface coating.

“Allied BioScience has been committed to reducing the global burden of infectious disease for over a decade, but we’re especially proud of the innovation over the past year,” said Michael Ruley, CEO of Allied BioScience. “We remain focused on our mission as we expand globally, providing SurfaceWise2 to nations as part of the fight against COVID-19 and other viruses, and continue to diversify our products to keep our friends and families safer in new ways.”

Following initial emergency use authorization for SurfaceWise2 in the State of Texas by the Environmental Protection Agency, the company continues to work closely with the agency to increase access to the revolutionary residual COVID-19-fighting solution. The EPA recently announced the expansion of this authorization for the states of Oklahoma and Arkansas, as well as an approved extended residual efficacy of 30 days. Broad, national approval is expected in the coming months.

The company recently relocated its Plano headquarters to a new office space with nearly double its previous square footage to account for anticipated team expansion and plans to expand offerings outside of its flagship surface coatings in 2021.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine